Skip to content
OpenCapital
Get started

Kymera Therapeutics KYMR Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Pfizer logo
PfizerPFE
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's available for sale securities debt securities current?
Kymera Therapeutics (KYMR) reported available for sale securities debt securities current of $506.84M in Q1 2026.
How has Kymera Therapeutics's available for sale securities debt securities current changed year-over-year?
Kymera Therapeutics's available for sale securities debt securities current increased by 35.8% year-over-year, from $373.18M to $506.84M.
What is the long-term trend for Kymera Therapeutics's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Kymera Therapeutics's available for sale securities debt securities current has grown at a 13.1% compound annual growth rate (CAGR), from $265.2M to $491.27M.